Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Taurursodiol

FDA-approved product (for suspension, oral).

Registered studies
43
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Taurursodiol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Taurursodiol. Its therapeutic class is shown instead.

WHO therapeutic group
Bile acids and derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA79.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Taurursodiol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Taurursodiol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

    NCT04987671 · start 2021-08-05

    Registered record
    Registry ID
    NCT04987671
    Conditions
    ALS
    Interventions
    AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-08-05
    Completion
    2023-09
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALS
    InterventionAMX0035
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

    NCT04727320 · start 2021-03-05

    Registered record
    Registry ID
    NCT04727320
    Conditions
    Liver Cirrhosis
    Interventions
    Tauroursodeoxycholic acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-03-05
    Completion
    2021-07-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    InterventionTauroursodeoxycholic acid; Placebo
    PhaseEarly phase 1
    Registry statusUnknown

  • A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

    NCT04516096 · start 2020-11-22

    Registered record
    Registry ID
    NCT04516096
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-11-22
    Completion
    2023-01-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionAMX0035
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Targeting ER Stress in Vascular Dysfunction

    NCT04001647 · start 2019-06-01

    Registered record
    Registry ID
    NCT04001647
    Conditions
    Vasodilation; Arterial Stiffness
    Interventions
    Acetylcholine; Sodium Nitroprusside; Ascorbic Acid
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2019-06-01
    Completion
    2022-08-16
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasodilation; Arterial Stiffness
    InterventionAcetylcholine; Sodium Nitroprusside; Ascorbic Acid
    PhaseEarly phase 1
    Registry statusTerminated

  • Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

    NCT03800524 · start 2019-02-22

    Registered record
    Registry ID
    NCT03800524
    Conditions
    Amyotrophic Lateral Sclerosis (ALS)
    Interventions
    Tauroursodeoxycholic Acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-02-22
    Completion
    2023-12-31
    Enrolment
    337

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis (ALS)
    InterventionTauroursodeoxycholic Acid; Placebo
    PhasePhase 3
    Registry statusUnknown

  • TUDCA as a Therapy for Ulcerative Colitis (UC)

    NCT04114292 · start 2019-01-17

    Registered record
    Registry ID
    NCT04114292
    Conditions
    Ulcerative Colitis
    Interventions
    Tauroursoursodeoxycholic acid, brand name Tudcabil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-17
    Completion
    2022-06-07
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionTauroursoursodeoxycholic acid, brand name Tudcabil
    PhasePhase 1
    Registry statusCompleted

  • Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma

    NCT03878654 · start 2019-01-10

    Registered record
    Registry ID
    NCT03878654
    Conditions
    Asthma
    Interventions
    Tauroursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-01-10
    Completion
    2019-09-11
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionTauroursodeoxycholic Acid
    PhasePhase 1
    Registry statusTerminated

  • Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

    NCT03533257 · start 2018-09-14

    Registered record
    Registry ID
    NCT03533257
    Conditions
    Alzheimer Disease
    Interventions
    AMX0035; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-09-14
    Completion
    2020-11-06
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionAMX0035; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

    NCT03423121 · start 2018-06-19

    Registered record
    Registry ID
    NCT03423121
    Conditions
    Progressive Multiple Sclerosis
    Interventions
    Tauroursodeoxycholic Acid; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-06-19
    Completion
    2022-07-05
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Multiple Sclerosis
    InterventionTauroursodeoxycholic Acid; Placebo oral capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin

    NCT03481972 · start 2018-04-11

    Registered record
    Registry ID
    NCT03481972
    Conditions
    TTR Cardiac Amyloidosis
    Interventions
    Doxycycline and tauroursodeoxycholic acid; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-11
    Completion
    2023-06-22
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTTR Cardiac Amyloidosis
    InterventionDoxycycline and tauroursodeoxycholic acid; Standard of care
    PhasePhase 3
    Registry statusCompleted

  • Effects of TUDCA on Endothelial Function in Type 2 DM

    NCT03462940 · start 2018-04-02

    Registered record
    Registry ID
    NCT03462940
    Conditions
    Diabetes Mellitus, Type 2; Insulin Response; Endothelial Dysfunction
    Interventions
    Tauroursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-04-02
    Completion
    2021-02-09
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Insulin Response; Endothelial Dysfunction
    InterventionTauroursodeoxycholic acid
    PhaseNot applicable
    Registry statusTerminated

  • Open Label Extension Study of AMX0035 in Patients With ALS

    NCT03488524 · start 2018-03-29

    Registered record
    Registry ID
    NCT03488524
    Conditions
    Amyotrophic Lateral Sclerosis; ALS
    Interventions
    AMX0035
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-29
    Completion
    2021-03-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis; ALS
    InterventionAMX0035
    PhasePhase 2
    Registry statusCompleted

  • Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

    NCT03431896 · start 2018-02-01

    Registered record
    Registry ID
    NCT03431896
    Conditions
    Amyloidosis; Amyloid; Amyloid Neuropathies, Familial; Amyloid Cardiomyopathy; Amyloid - Primary; Transthyretin Amyloidosis; AL Amyloidosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-01
    Completion
    2026-03-09
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Amyloid; Amyloid Neuropathies, Familial; Amyloid Cardiomyopathy +3 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    NCT03127514 · start 2017-06-22

    Registered record
    Registry ID
    NCT03127514
    Conditions
    Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Neuromuscular Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Nervous System Diseases; Central Nervous System Diseases
    Interventions
    AMX0035; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-22
    Completion
    2019-11-24
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis; Motor Neuron Disease; Neuromuscular Diseases; Neurodegenerative Diseases +4 more
    InterventionAMX0035; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

    NCT03331432 · start 2015-10-28

    Registered record
    Registry ID
    NCT03331432
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Tauroursodeoxycholic acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-10-28
    Completion
    2018-02-14
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionTauroursodeoxycholic acid; Placebo
    PhaseNot applicable
    Registry statusCompleted